⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864723 | 0.93 | — | — | |
| SCHEMBL248319 | 0.84 | — | — | |
| SCHEMBL2010715 | 0.81 | — | — | |
| SCHEMBL2001917 | 0.80 | — | — | |
| SCHEMBL3972801 | 0.79 | PIK3CD (0.35) | — | |
| SCHEMBL2099518 | 0.78 | GLB1 (0.35) | — | |
| SCHEMBL1429910 | 0.76 | HTR7 (0.31) | — | |
| SCHEMBL1080135 | 0.76 | GNAO1 (0.41) | — | |
| SCHEMBL4728766 | 0.75 | — | — | |
| SCHEMBL10699311 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| US-20230348437-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | claimed |
| EP-4175642-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2023-05-10 | — | — | EP | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-114127065-A | Compounds for the treatment of neurodegenerative diseases and cancer | 鸿仪有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | claimed |
| EP-3935057-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES AND CANCERS | Hongyi & Associates LLC (US) | 2022-01-12 | — | — | EP | claimed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | claimed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | claimed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | claimed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| CN-1206004-A | New substituted azetidinones and their use | MERCK & CO INC (US) | 1999-01-27 | — | — | CN | claimed |
| CN-1090272-A | Novel substituted azetidinones as anti-inflammatory and anti-allergic agents | MERCK & CO INC (US) | 1994-08-03 | — | — | CN | claimed |
| EP-0378111-B1 | Isoxazole derivatives having anti-serotonin activity, their preparation process and compositions containing them | ZAMBON SPA (IT) | 1994-06-01 | — | — | EP | claimed |
| US-4988691-A | Analgesics, cardiovascular disorders, nervous system disorders | ZAMBON GROUP S.P.A. (IT) | 1991-01-29 | — | — | US | claimed |
| EP-0378111-A1 | Isoxazole derivatives having anti-serotonin activity, their preparation process and compositions containing them | ZAMBON GROUP S.p.A. (IT) | 1990-07-18 | — | — | EP | claimed |
| US-4174320-A | Process for the preparation of rifampicin | HOLCO INVESTMENT INC. (PA) | 1979-11-13 | — | — | US | claimed |